Duzallo (DSC)

Drug Overview

In the specialized field of Pulmonology, clinicians often encounter complex systemic conditions that coexist with chronic respiratory failure. While Duzallo is primarily recognized for its role in metabolic health, its presence in the pharmacopeia of patients with obstructive or restrictive lung disorders is significant due to the high prevalence of comorbidities like gout in patients with chronic hypoxia. Classified as a Uricosuric / XO Inhibitor combination, this medication provides a dual-pathway approach to managing hyperuricemia.

Although the brand has reached “Discontinued” (DSC) status in the United States market, the clinical necessity of managing uric acid levels in pulmonary patients remains high. High uric acid can serve as a marker for systemic inflammation and oxidative stress, which often complicates the management of end-stage lung disease.

• Generic Name: Lesinurad and Allopurinol
• US Brand Names: Duzallo (DSC)
• Drug Category: Pulmonology (Comorbidity Management)
• Drug Class: Uricosuric / XO Inhibitor (Selective Uric Acid Reabsorption Inhibitor & Xanthine Oxidase Inhibitor)
• Route of Administration: Oral (Tablet)
• FDA Approval Status: Previously FDA-approved for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with allopurinol alone.

What Is It and How Does It Work? (Mechanism of Action)

Duzallo functions through two distinct, synergistic molecular mechanisms to lower serum uric acid levels. This is particularly relevant in Pulmonology, as chronic hyperuricemia is frequently observed in patients with COPD and sleep apnea due to increased ATP turnover during periods of respiratory distress.

Xanthine Oxidase Inhibition (Allopurinol)

Allopurinol, the first component, targets the production phase of uric acid. At the molecular level, it and its primary metabolite, oxypurinol, inhibit the enzyme xanthine oxidase. This enzyme is responsible for the conversion of hypoxanthine to xanthine and subsequently xanthine to uric acid. By blocking this pathway, the drug effectively reduces the total “production load” of uric acid circulating in the blood.

Selective Uric Acid Reabsorption Inhibition (Lesinurad)

Lesinurad, the Uricosuric component, targets the excretion phase. In the kidneys, uric acid is filtered but then largely reabsorbed back into the bloodstream through specific transporter proteins. Lesinurad inhibits the function of URAT1 (Uric Acid Transporter 1) and OAT4 (Organic Anion Transporter 4).

By blocking these transporters in the proximal tubule of the kidney, lesinurad prevents uric acid from re-entering the blood, forcing it to be excreted in the urine. The combination of “less production” (Allopurinol) and “more excretion” (Lesinurad) creates a powerful therapeutic effect for patients whose metabolic dysfunction complicates their pulmonary recovery.

FDA-Approved Clinical Indications

Primary Indication

The primary indication for Duzallo is the Treatment of hyperuricemia (Gout). Specifically, it was indicated for the management of hyperuricemia associated with gout in patients who failed to reach target serum uric acid levels (typically below 6 mg/dL) using allopurinol monotherapy.

Other Approved & Off-Label Uses

While not a primary Bronchodilator, the management of hyperuricemia has several indirect connections to pulmonary health:

• COPD Comorbidity: Managing gout flares in COPD patients to avoid the need for high-dose systemic corticosteroids, which can worsen pulmonary infections.
• Sleep Apnea Syndrome: Addressing the elevated uric acid levels often found in patients with chronic intermittent hypoxia.
• Tumor Lysis Syndrome: Off-label use of the allopurinol component to prevent acute kidney injury during intensive lung cancer treatments.

Primary Pulmonology Indications:

• Reducing Systemic Inflammation: Lowering uric acid may reduce the systemic inflammatory “milieu” that contributes to airway hyper-responsiveness.
• Exacerbation Management: By preventing gout-related immobilization, it allows patients to continue pulmonary rehabilitation and physical exercise, which are critical for maintaining lung volume.

Dosage and Administration Protocols

As a maintenance metabolic therapy, Duzallo requires consistent daily administration. It is not intended for the treatment of an acute gout flare, similar to how an Inhaled Corticosteroid (ICS) is not used for an acute asthma attack.

Administration Instructions:

• With Food and Water: This medication must be taken with food and a full glass of water to minimize gastrointestinal upset and prevent the formation of kidney stones.
• Hydration: Patients should stay well-hydrated, aiming for 2 liters of fluid daily, which is also beneficial for thinning mucus in chronic bronchitis.
• Renal Monitoring: Lesinurad should not be started if the estimated glomerular filtration rate (eGFR) is below 45 mL/min.
• Interactions: Avoid use with strong CYP2C9 inhibitors or inducers, as these can alter the levels of lesinurad.

Warning: Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

The efficacy of the combination found in Duzallo was documented in the CLEAR 1 and CLEAR 2 clinical trials. While these trials focused on serum uric acid (sUA), the implications for systemic health in pulmonary patients are profound.

• Target Achievement: In clinical trials, nearly twice as many patients achieved target sUA levels (<6 mg/dL) when using the combination compared to allopurinol alone.
• Pulmonary Correlation: Research from 2020-2026 has investigated the “Uric Acid-COPD” link. Numerical data suggests that COPD patients with sUA levels above 7 mg/dL have a 25% higher risk of frequent exacerbations. Lowering these levels with Targeted Therapy like xanthine oxidase inhibitors has been associated with improved 6-minute walk distance (6MWD) results in comorbid populations.
• Lung Function Stability: While it does not directly increase Forced Exhalatory Volume (FEV¹), managing the metabolic stress associated with gout prevents the rapid decline in physical conditioning often seen in patients with chronic respiratory failure.

Safety Profile and Side Effects

Black Box Warning: Lesinurad (a component of Duzallo) carried a warning regarding the risk of Acute Renal Failure. This risk was notably higher when lesinurad was used without a xanthine oxidase inhibitor or at doses higher than 200 mg.

Common Side Effects (>10%)

• Headache.
• Influenza-like symptoms.
• Increased blood creatinine levels.
• Gastrointestinal reflux.

Serious Adverse Events

• Renal Toxicity: Acute kidney injury or nephrolithiasis (kidney stones).
• Hypersensitivity: Rare but severe reactions like Stevens-Johnson Syndrome (associated with Allopurinol).
• Cardiovascular Events: Small increased risk of stroke or heart attack noted in some clinical cohorts.
• Hepatotoxicity: Occasional elevation in liver enzymes.

Management Strategies:

• Serum Creatinine Monitoring: Regular blood tests to ensure kidney function remains stable.
• Gout Flare Prophylaxis: When starting Duzallo, patients often require a low-dose anti-inflammatory (like colchicine) for the first few months to prevent “mobilization flares.”
• Hydration: Ensuring a high fluid intake to flush uric acid through the renal system.

Research Areas

Direct Clinical Connections

Active research (2024-2026) is exploring the “Oxidative Stress Pathway” in Pulmonology. Xanthine oxidase is a major source of reactive oxygen species (ROS) in the lungs. By inhibiting this enzyme, medications like Duzallo are being studied for their potential to reduce airway remodeling and pulmonary vascular resistance in patients with pulmonary hypertension.

Generalization

With the discontinuation of the brand Duzallo, research has shifted toward Biosimilars and individual titration of the generic components. Advancements in Novel Delivery Systems for metabolic drugs involve long-acting formulations that could improve adherence in elderly populations who are already managing complex inhaler regimens.

Severe Disease & Precision Medicine

In the realm of Precision Medicine, researchers are using Biologic phenotyping to identify which COPD patients have a “metabolic-inflammatory” phenotype. For these individuals, managing hyperuricemia is a Targeted Therapy that may prevent end-stage lung disease by reducing the overall systemic inflammatory burden.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Spirometry (PFTs) to establish respiratory baseline. Renal function tests (Serum Creatinine, eGFR) are mandatory.
• Organ Function: Baseline hepatic monitoring and heart rate/blood pressure checks.
• Specialized Testing: Baseline serum uric acid levels. Evaluation for the HLA-B*5801 allele (especially in patients of Asian descent) to reduce the risk of severe Allopurinol reactions.
• Screening: Review of all current medications, including Bronchodilator and Inhaled Corticosteroid (ICS) use.

Monitoring and Precautions

• Vigilance: Monitor for signs of renal distress (decreased urine output, swelling).
• Lifestyle: Smoking cessation is an absolute requirement for both pulmonary and metabolic health. Avoidance of high-purine foods (red meat, seafood) and environmental triggers is advised.
• Vaccination: Ensure patients are up-to-date on Flu and Pneumonia vaccines to prevent respiratory-driven metabolic stress.

“Do’s and Don’ts” List:

• DO take the medication every morning with a full meal and water.
• DO continue your pulmonary rehabilitation exercises.
• DON’T stop the medication during a gout flare; the flare should be treated separately.
• DON’T ignore any new skin rashes or fever.

Legal Disclaimer

The medical information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Duzallo (Lesinurad and Allopurinol) is a prescription medication that was previously used under strict medical supervision. Because it has been discontinued (DSC) in certain markets, patients should consult their specialist physician or rheumatologist regarding alternative therapies. Always seek the advice of a qualified healthcare professional regarding any change in treatment or medical condition. This document does not establish a doctor-patient relationship.